Caregiver | Jotup

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on:

Monday, March 25, 2024

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points:

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
“We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

Musicians On Call’s Programs Expand Nationwide to Deliver the Healing Power of Music to Hospitals When Needed Most

Retrieved on:

Monday, March 25, 2024

Blood pressure, Volunteering, Caregiver, Patient, Hospital, American Hospital Association, City, Music, MOC, HCA Healthcare

Through Musicians On Call’s bedside and virtual programs, patients experience the physical, mental and emotional benefits of live music in the hospital setting.

Key Points:

Through Musicians On Call’s bedside and virtual programs, patients experience the physical, mental and emotional benefits of live music in the hospital setting.
“For nearly four years, volunteer and visitor restrictions in local hospitals paused Musicians On Call’s in-person programs.
“Our commitment to enhancing the hospital environment through the transformative power of music continues as the demand for our programs grows.
As the nation’s leading provider of live music in hospitals, MOC volunteers have performed for more than one million individuals in healthcare facilities nationwide.

Congress Passes Bills Making Major Investments in Alzheimer’s

Retrieved on:

Saturday, March 23, 2024

Congress, Medical imaging, Caregiver, Health equity, DSM-IV codes, Research, National Institute on Aging, National coverage determination, Investment, CDC, NINDS, Language, Dementia, NIA, Medicare, NCD, CMS, Pharmaceutical industry

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.

Key Points:

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.
“We are thrilled to witness Congress’s steadfast 12-year commitment to Alzheimer’s research, despite ongoing budget restraints,” said UsAgainstAlzheimer’s chair and co-founder George Vradenburg.
UsAgainstAlzheimer’s worked to include language encouraging diversity in clinical trials, and the establishment of a brain health equity initiative to improve the integration of brain health into primary care, particularly within underrepresented communities.
The bill also encourages the National Institute of Biomedical Imaging and Bioengineering to collaborate with National Institute of Aging (NIA) and The National Institute of Neurological Disorders and Stroke (NINDS) to develop new technologies that could discover the earliest biological events that lead to Alzheimer’s disease and related dementias.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on:

Thursday, March 21, 2024

SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points:

In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Thursday, March 21, 2024

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the fourth quarter and full year 2023.

Key Points:

In February 2024, ARS Pharma announced the successful completion of the repeat dosing study of neffy in seasonal allergic rhinitis under nasal allergen challenge conditions.
R&D Expenses: Research and development expenses were $3.4 million and $20.3 million for the quarter and year ended December 31, 2023, respectively.
G&A Expenses: General and administrative expenses were $6.8 million and $47.3 million for the quarter and year ended December 31, 2023, respectively.
Net Loss: Net loss was $7.2 million and $54.4 million for the quarter and year ended December 31, 2023, respectively.

Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease

Retrieved on:

Wednesday, March 20, 2024

Senior, Patient, Caregiver, Safety, Pharmaceutical industry

MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD).

Key Points:

MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD).
"We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our Alzheimer’s study, which was completed in February.
To clean data this fast is truly a tremendous achievement,” said Cheng Fang, Ph.D., Senior Vice President of Annovis.
Over 700 patients were screened with a total of 353 patients enrolled and 327 patients completed the study.

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

Retrieved on:

Wednesday, March 20, 2024

TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the details of its U.S. commercial launch of Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200, the first FDA-approved therapy for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile, (PSEJ), or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD).

Key Points:

Prior to Lenmeldy, there were no treatment options in the U.S. for early-onset MLD beyond supportive and end-of-life care.
This approach has the potential to restore enzymatic function to stop or slow disease progression with a single treatment.
Utilizing results from such studies, a multi-stakeholder working group is finalizing a nomination to add MLD to the U.S.
Based on current timelines and assumptions, Orchard Therapeutics expects the nomination will be submitted in mid-year 2024.

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Retrieved on:

Tuesday, March 19, 2024

AEON, MMD, Patent, Caregiver, Headache, Migraine, Patient, Injection, Safety, AB toxin, Phase II, FDA, Food, MHD, Pharmaceutical industry

IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced a productive end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) following the Phase 2 data in episodic migraine previously released in October 2023, that supports advancing ABP-450 (prabotulinumtoxinA) injection into the proposed pivotal Phase 3 program. As part of the updated development plan, the Company will now conduct an interim analysis of the ongoing Phase 2 study of ABP-450 for the preventive treatment of chronic migraine and anticipates releasing the data in the second quarter of 2024.

Key Points:

Patients have at least a one-year history of migraine (with or without aura) according to the ICHD-3 (2018) definition and diagnostic criteria.
All patients will receive two treatment cycles 12 weeks apart utilizing the Company’s patented treatment paradigm (U.S. Patent No.
11,826,405) involving fewer injections than the current botulinum toxin treatment option for migraine.
The interim analysis will include approximately 100 chronic migraine patients in each of the three arms that have completed the two 12-week treatment cycles.

Saint Peter’s Leads as First NJ Health System with Upfront Tuition Coverage for Employees

Retrieved on:

Tuesday, March 19, 2024

Education, Arizona State University, Learning, Caregiver, Partnership, City University, Policy, University, CUNY, LOS, LEAP, Saint, Nursing

The Learning, Education and Advancement Program (LEAP) , available to Saint Peter’s full- and part-time employees, makes educational growth accessible so employees can earn valuable credentials and degrees to advance their professional careers in health care.

Key Points:

The Learning, Education and Advancement Program (LEAP) , available to Saint Peter’s full- and part-time employees, makes educational growth accessible so employees can earn valuable credentials and degrees to advance their professional careers in health care.
The initiative complements Saint Peter’s existing tuition reimbursement policy, improving access to learning by lowering the financial barrier of upfront tuition costs for employees.
“As a mission-based healthcare system, this program underscores Saint Peter’s commitment to transforming careers and our community,” said Laura Atkinson, vice president and chief human resources officer at Saint Peter’s Healthcare System.
"Saint Peter’s shares our dedication to advancing employees’ careers through equitable access to education," said Craig Maloney, CEO of InStride.

Primacorp Ventures Inc. Provides Free Breakfast to Ukrainian Refugees

Retrieved on:

Tuesday, March 19, 2024

Employment, Real estate, CDI College, Conference, Caregiver, CDI, Business, Education, Reeves College, History, Art, Refugee, Workforce, Vancouver Career College, MOSAIC, Tourism

Calgary, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- Primacorp Foundations, the philanthropic arm of Primacorp Ventures Inc., has initiated a new project to provide assistance to refugees.

Key Points:

Calgary, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- Primacorp Foundations, the philanthropic arm of Primacorp Ventures Inc., has initiated a new project to provide assistance to refugees.
The hotel the Ukrainian refugees are currently residing in is owned by Primacorp Ventures and operated by Primacorp’s Real Estate division.
Primacorp Ventures provides exceptional care and support to Ukrainian refugees.
Together with its business divisions in real estate and healthcare, Primacorp Ventures focuses on changing lives through education, service, and care.